Arena Pharmaceuticals Inc (ARNA)

The total asset value of Arena Pharmaceuticals Inc (ARNA) stood at $ 785 Mln as on 31-Dec-21

The share price of Arena Pharmaceuticals Inc (ARNA) is $99.99 (NASDAQ) as of 14-Mar-2022 09:30 EST. Arena Pharmaceuticals Inc (ARNA) has given a return of 29.86% in the last 3 years.

Arena Pharmaceuticals Inc (ARNA) has a market capitalisation of $ 6,165 Mln as on 14-Mar-2022. As per Value Research classification, it is a company.

The P/B ratio of Arena Pharmaceuticals Inc (ARNA) is 9.16 times as on 14-Mar-2022, a 2.61% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Arena Pharmaceuticals Inc (ARNA) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Arena Pharmaceuticals Inc (ARNA) and enter the required number of quantities and click on buy to purchase the shares of Arena Pharmaceuticals Inc (ARNA).

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

The CEO & director of Mr. Amit D. Munshi M.B.A.. is Arena Pharmaceuticals Inc (ARNA), and CFO & Sr. VP is Ms. Laurie D. Stelzer.

The promoters of Arena Pharmaceuticals Inc (ARNA) have pledged 0% of the total equity as on Feb-22.

Some of the close peers are:

No, TTM profit after tax of Arena Pharmaceuticals Inc (ARNA) was $-616 Mln.